IDH1 and acute myeloid leukemia: Enasidenib and Ivosidenib, inhibitors for isocitrate dehydrogenase 1 and 2 (IDH1/2), were approved for treating relapsed or refractory acute myeloid leukemia (AML) in 2017 and 2018, respectively [95].